Meta Pixel

News and Announcements

Crypto (DeFi) Focused Systematic Investment Fund and Platform with a 90% Customer Retention Rate | Average Return of 23.10%

  • Published December 16, 2021 12:00AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

“Having a systematic approach to investing gives you conviction and tools to use when markets get volatile. Using machines to their fullestwhile augmenting that with human intelligence, can be an incredible edge.”

Charles Meaden, CEO & Co-Founder – Gembot

Executive Summary

Gembot is a FinTech and Fund with an AI investment platform that democratises investment strategies and tools for consumers. Gembot focuses on small and mid-cap US equities, derivatives, and crypto, specifically DeFi. Since its inception, Gembot has averaged a 23.10% return per 120-day cycle.

Investment Highlights

  • The company’s highest return on a 120-day fund is 94.73% after fees.

  • Gembot has closed seventeen 120-day funds with a win rate of 83.25% and an average return of 23.10%.

  • The company’s customer retention rate over 18 months is 90%.

  • Its team and board are experienced in technology. Gembot’s founder has sold a gaming platform and the lead investor and Chair of the Board has invested in four other technology companies.

Investment Offering

Gembot is raising capital through a debt offering and has already raised $2.3M in equity.

Register Interest

Capital Insights
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer

In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]

Capital Insights
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts

As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.

Join over 45,000+ sophisticated investors

Join Now